CTOs on the Move

MaxThera

www.maxthera.com

 
MaxThera, Inc. is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.maxthera.com
  • 100 Cummings Ctr Ste 419E
    Beverly, MA USA 01915
  • Phone: 978.927.8900

Executives

Name Title Contact Details

Similar Companies

Advanced Physical Medicine of

Advanced Physical Medicine of is a Yorkville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CERTUS PHARMACEUTICALS

CERTUS PHARMACEUTICALS is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChemCon America

ChemCon America is a Lake Mary, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valeo Pharma

Founded in 2003, Valeo Pharma is a Canadian Pharma Company with a long history of successfully driving #healthcareinnovationforcanadians by commercializing pharmaceutical products in Canada and is therapeutically focused on respiratory diseases, neurodegenerative diseases, specialty products, and oncology.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.